Tonix Pharmaceuticals(NASDAQ:TNXP) 
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases an...
Website: http://www.tonixpharma.com
Founded: 2007
IPO Price: $4.25 (Aug 09, 2013)
Full Time Employees: 16
Sector: Healthcare
Industry: Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
product revenue | 6,878,000 | 5,390,000 | 3,290,000 | 1,998,000 | 2,429,000 | 2,582,000 | 2,822,000 | 2,208,000 | 2,482,000 | 3,779,000 | 3,989,000 | |||||||||||||||||||||||||||||||||||||||||||||||
costs and expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of sales | 1,578,000 | 943,000 | 1,660,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
research and development | 18,213,000 | 16,941,000 | 9,289,000 | 10,820,000 | 7,436,000 | 8,297,000 | 9,114,000 | 9,698,000 | 12,863,000 | 17,120,000 | 21,050,000 | 21,976,000 | 26,511,000 | 24,674,000 | 22,201,000 | 16,579,000 | 18,422,000 | 22,296,000 | 13,082,000 | 18,133,000 | 15,327,000 | 12,097,000 | 8,813,000 | 10,571,000 | 4,676,000 | 5,690,000 | 5,052,000 | 3,554,000 | 3,896,000 | 5,057,000 | 3,264,000 | 4,067,000 | 5,170,000 | 3,634,000 | 3,908,000 | 2,806,000 | 2,994,000 | 4,880,000 | 5,466,000 | 7,516,000 | 10,671,000 | 9,490,000 | 10,314,000 | 8,871,000 | 6,829,000 | 5,775,000 | 5,217,000 | 4,075,000 | 3,550,000 | 1,328,549 | 1,636,827 | 943,995 | 740,629 | 699,749 | 658,143 | 827,788 | 397,628 | |
selling general and administrative | 28,624,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total operating expenses | 48,415,000 | 30,294,000 | 18,483,000 | 23,833,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating income | -41,537,000 | -48,286,000 | -33,067,000 | -28,296,000 | -16,054,000 | -22,480,000 | -15,554,000 | -77,316,000 | -21,351,000 | -27,329,000 | -28,147,000 | -29,002,000 | -33,902,000 | -32,728,000 | -29,591,000 | -23,336,000 | -26,436,000 | -29,479,000 | -18,535,000 | -23,562,000 | -17,023,000 | -11,999,000 | -14,192,000 | -8,734,000 | -7,891,000 | -5,906,000 | -6,297,000 | -7,650,000 | -5,541,000 | -6,143,000 | -6,988,000 | -5,543,000 | -5,835,000 | -4,822,000 | -5,091,000 | -7,510,000 | -7,609,000 | -9,836,000 | -14,014,000 | -13,402,000 | -13,280,000 | -11,784,000 | -9,696,000 | -9,004,000 | -7,434,000 | -6,049,000 | -5,169,000 | -3,709,406 | -3,091,680 | -2,085,689 | -2,001,225 | -1,915,765 | -1,734,342 | -1,850,939 | -1,160,365 | |||
yoy | 158.73% | 114.80% | 112.59% | -63.40% | -24.81% | -17.74% | -44.74% | 166.59% | -37.02% | -16.50% | -4.88% | 24.28% | 28.24% | 11.02% | 59.65% | -0.96% | 73.17% | 54.47% | 66.02% | 94.90% | 52.06% | 140.30% | 14.17% | 42.41% | -3.86% | -9.89% | 38.01% | -5.04% | 27.40% | 37.26% | -26.19% | -23.31% | -50.98% | -63.67% | -43.96% | -42.70% | -16.53% | 44.53% | 48.84% | 78.64% | 94.81% | 87.58% | 142.73% | 140.45% | 190.02% | 158.29% | 93.63% | 78.26% | 12.68% | 72.47% | ||||||||
qoq | -13.98% | 46.02% | 16.86% | 76.26% | -28.59% | 44.53% | -79.88% | 262.12% | -21.87% | -2.91% | -2.95% | -14.45% | 3.59% | 10.60% | 26.80% | -11.73% | -10.32% | 59.05% | -21.34% | 41.87% | -15.45% | 10.68% | 33.61% | -6.21% | -17.69% | 38.06% | -9.80% | -12.09% | 26.07% | -5.00% | 21.01% | -5.28% | -32.21% | -1.30% | -22.64% | -29.81% | 4.57% | 0.92% | 12.70% | 21.53% | 7.69% | 21.12% | 22.90% | 17.02% | 39.35% | 19.98% | 48.23% | 4.22% | 4.46% | 10.46% | -6.30% | 59.51% | ||||||
grant income | 71,000 | 982,000 | 1,036,000 | 923,000 | 926,000 | 1,668,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on extinguishment of debt | -2,092,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest income | 1,346,000 | 1,344,000 | 1,231,000 | 943,000 | 428,750 | 172,000 | 897,000 | 1,048,000 | 610,000 | -74,000 | 7,000 | 2,000 | 9,000 | 13,000 | 24,000 | 27,000 | 53,000 | 66,000 | 64,000 | 62,000 | 62,000 | 56,000 | 53,000 | 50,000 | 49,000 | 42,000 | 27,000 | 28,000 | 31,000 | 30,000 | 38,000 | 42,000 | 30,000 | 15,000 | ||||||||||||||||||||||||
other expense | -3,000 | -39,000 | -1,156,000 | -1,955,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss available to common stockholders | -40,194,000 | -46,910,000 | -32,010,000 | -28,272,000 | -16,829,000 | -22,108,000 | -14,213,000 | -78,776,000 | -14,939,000 | -27,322,000 | -27,975,000 | -28,356,000 | -34,084,000 | -28,981,000 | -27,395,000 | -29,553,000 | -18,528,000 | -23,553,000 | -17,021,000 | -11,990,000 | -14,179,000 | |||||||||||||||||||||||||||||||||||||
net loss to common stockholders per common share, basic and diluted | -2,930 | -2,840 | -180 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average common shares outstanding, basic and diluted | 13,707,104,000 | 8,922,792,000 | 7,327,257,000 | 5,927,231,000 | 736,339,000 | 62,122,283,000 | 4,085,132,000 | 80,879,108,000 | 17,039,309,000 | 15,327,558,000 | 10,587,096,000 | 63,352,898,000 | 35,739,057,000 | 41,944,289,000 | 22,404,371,000 | 522,060,899,000 | 360,215,323,000 | 366,425,157,000 | 331,281,242,000 | 290,106,510,000 | 94,591,715,000 | 127,199,834,000 | 62,391,006,000 | 1,608,568,000 | 1,377,857,000 | 4,848,199,000 | 9,587,025,000 | 8,391,709,000 | 7,850,298,000 | 6,665,091,000 | 7,508,036,000 | 7,327,890,000 | 3,985,529,000 | 2,521,016,000 | 26,131,085,000 | 19,736,434,000 | 18,860,429,000 | 16,791,059,000 | 18,423,816,000 | 16,137,898,000 | 13,696,482,000 | 9,985,515,000 | 10,496,504,000 | 9,923,184,000 | 8,718,199,000 | 3,231,311,000 | 3,537,490 | 2,186,537 | 2,159,130 | 33,868,320 | 34,278,432 | 34,278,432 | 31,650,490 | |||||
revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of revenue | 1,395,500 | 1,367,000 | 3,272,000 | 1,645,500 | 1,555,000 | 3,367,000 | 593,500 | 2,374,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
selling, general and administrative | 35,677,000 | 25,701,000 | 16,202,000 | 15,582,000 | 7,707,000 | 7,502,000 | 5,782,750 | 8,712,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
asset impairment charges | 58,957,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
costs and expenses: - sum | 21,283,500 | 36,357,000 | 30,433,250 | 18,376,000 | 79,524,000 | 32,728,000 | 29,591,000 | 23,336,000 | 26,436,000 | 29,479,000 | 18,535,000 | 23,562,000 | 20,736,000 | 17,023,000 | 11,999,000 | 14,192,000 | 7,297,000 | 8,734,000 | 7,891,000 | 5,906,000 | 6,297,000 | 7,650,000 | 5,541,000 | 6,143,000 | 6,988,000 | 5,543,000 | 5,835,000 | 4,822,000 | 5,091,000 | 7,510,000 | 7,609,000 | 9,836,000 | 14,014,000 | 13,402,000 | 13,280,000 | 11,784,000 | 9,696,000 | 9,004,000 | 7,434,000 | 6,049,000 | 5,169,000 | 3,709,406 | 3,091,680 | 2,085,689 | 2,001,225 | 1,915,765 | 1,734,342 | 1,160,365 | ||||||||||
gain on change in fair value of warrant liabilities | -855,000 | 7,005,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss per common share, basic and diluted | -2,605 | -3,590 | -3,860 | -1,165 | -230 | -19,280 | -1,850 | -1,830 | -2,680 | -520 | -210 | -690 | -1,220 | -50 | -70 | -50 | -70 | -60 | -90 | -230 | 4,600 | -5,690 | -950 | -1,290 | -24,660 | -570 | -730 | -880 | -680 | -770 | -650 | -1,270 | -13,960 | -290 | -500 | -740 | -710 | -720 | -730 | -710 | -850 | -710 | -610 | -590 | -3,367.27 | -0.87 | -0.95 | -0.93 | -0.08 | -0.05 | -0.09 | -0.06 | ||||||
general and administrative | 10,104,000 | 9,310,000 | 7,026,000 | 7,391,000 | 8,054,000 | 7,390,000 | 6,757,000 | 8,014,000 | 7,183,000 | 5,453,000 | 5,429,000 | 5,409,000 | 4,926,000 | 3,186,000 | 3,621,000 | 2,621,000 | 3,044,000 | 2,839,000 | 2,352,000 | 2,401,000 | 2,593,000 | 2,277,000 | 2,076,000 | 1,818,000 | 1,909,000 | 1,927,000 | 2,016,000 | 2,097,000 | 2,630,000 | 2,143,000 | 2,320,000 | 3,343,000 | 3,912,000 | 2,966,000 | 2,913,000 | 2,867,000 | 3,229,000 | 2,217,000 | 1,974,000 | 1,619,000 | 2,380,857 | 1,454,853 | 1,141,694 | 1,260,596 | 1,216,016 | 1,076,199 | 1,023,150 | 762,737 | ||||||||||
other income | 394,000 | -554,000 | -327,000 | -605,000 | -593,000 | 1,875 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
costs and expenses | 23,760,000 | 32,136,000 | 29,002,000 | 33,902,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | -27,322,000 | -27,975,000 | -28,356,000 | -33,005,000 | -31,680,000 | -28,981,000 | -23,140,000 | -26,417,000 | -29,553,000 | -18,528,000 | -23,553,000 | -17,021,000 | -11,990,000 | -14,179,000 | -8,707,000 | -7,838,000 | -5,840,000 | -6,233,000 | -7,588,000 | -5,479,000 | -6,087,000 | -6,935,000 | -5,493,000 | -5,786,000 | -4,780,000 | -5,064,000 | -7,482,000 | -7,578,000 | -9,806,000 | -13,976,000 | -13,360,000 | -13,250,000 | -11,763,000 | -9,681,000 | -8,989,000 | -7,419,000 | -6,044,000 | -5,164,000 | -3,707,004 | -3,090,132 | -2,085,661 | -2,001,203 | -2,628,895 | -1,732,027 | -3,073,690 | -2,014,988 | ||||||||||||
yoy | -13.76% | -3.47% | 22.54% | 24.94% | 7.20% | 56.42% | -1.75% | 73.63% | 54.53% | 66.11% | 95.49% | 52.97% | 142.79% | 14.75% | 43.06% | -4.06% | -10.12% | 38.14% | -5.31% | 27.34% | 36.95% | -26.58% | -23.65% | -51.25% | -63.77% | -44.00% | -42.81% | -16.64% | 44.37% | 48.63% | 78.60% | 94.62% | 87.47% | 142.49% | 140.09% | 189.79% | 158.04% | 41.01% | 78.41% | -32.14% | -0.68% | |||||||||||||||||
qoq | -2.33% | -1.34% | -14.09% | 4.18% | 9.31% | 25.24% | -12.40% | -10.61% | 59.50% | -21.33% | 41.96% | -15.44% | 11.09% | 34.21% | -6.31% | -17.86% | 38.49% | -9.99% | -12.23% | 26.25% | -5.06% | 21.05% | -5.61% | -32.32% | -1.27% | -22.72% | -29.84% | 4.61% | 0.83% | 12.64% | 21.51% | 7.70% | 21.16% | 22.75% | 17.04% | 39.30% | 19.96% | 48.16% | 4.22% | -23.88% | 51.78% | -43.65% | 52.54% | |||||||||||||||
preferred stock deemed dividend | 2,404,000 | 4,255,000 | 1,260,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest and other income | 646,000 | 196,000 | 19,000 | 9,000 | 83,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
warrant deemed dividend | 451,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted average common shares outstanding, basic and diluted | 8,511,318,000 | 24,028,970,000 | 6,167,012,000 | 1,094,867,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest and other financing costs | 21,000 | 6,250 | 15,000 | 5,000 | 5,000 | 2,402 | 1,548 | 28 | 22 | -713,130 | 440 | 1,297 | -901,646 | |||||||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of debt | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of warrant liability | 47,023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of warrants liability | -1,224,049 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-06-30 | 2020-03-31 | 2018-03-31 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2012-12-31 | 2012-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||||||||||||||
current assets: | |||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 185,470,000 | 207,637,000 | 190,055,000 | 125,331,000 | 131,716,000 | 98,776,000 | 28,233,000 | 4,156,000 | 7,049,000 | 24,948,000 | 6,914,000 | 25,617,000 | 71,975,000 | 120,229,000 | 139,978,000 | 145,478,000 | 140,435,000 | 178,660,000 | 182,970,000 | 165,719,000 | 164,214,000 | 30,665,000 | 19,253,000 | 34,355,000 | 19,943,000 | 18,941,000 | 15,644,000 | 14,938,000 | 8,427,000 | 19,175,000 | 33,009,000 | 48,737,000 | |||||||||||
accounts receivable | 8,820,000 | 6,271,000 | 3,481,000 | 2,320,000 | 3,312,000 | 3,683,000 | 4,013,000 | 3,339,000 | |||||||||||||||||||||||||||||||||||
inventory | 3,645,000 | 6,013,000 | 5,729,000 | 5,986,000 | 8,136,000 | 8,408,000 | 7,931,000 | 9,457,000 | 12,351,000 | 13,639,000 | 13,317,000 | 13,700,000 | |||||||||||||||||||||||||||||||
prepaid expenses and other current assets | 9,233,000 | 8,955,000 | 8,806,000 | 9,898,000 | 6,409,000 | 8,135,000 | 10,366,000 | 8,335,000 | 10,698,000 | 9,181,000 | |||||||||||||||||||||||||||||||||
total current assets | 207,168,000 | 228,876,000 | 208,071,000 | 143,535,000 | 149,573,000 | 119,002,000 | 50,543,000 | 25,287,000 | 30,098,000 | 47,768,000 | 31,337,000 | 51,329,000 | 83,726,000 | 130,777,000 | 151,139,000 | 191,747,000 | 152,989,000 | 189,049,000 | 195,082,000 | 177,269,000 | 173,165,000 | 57,627,000 | 33,396,000 | 20,682,000 | 35,485,000 | 23,432,000 | 27,140,000 | 29,221,000 | 33,660,000 | 30,654,000 | 46,359,000 | 57,189,000 | 50,314,000 | 59,986,000 | 39,036,000 | 46,926,000 | 44,816,000 | 50,101,000 | 8,631,000 | 7,466,331 | 114,399 | 2,010,049 | 1,412,272 |
property and equipment | 44,894,000 | 44,456,000 | 42,574,000 | 42,335,000 | 41,766,000 | 42,252,000 | 42,747,000 | 43,247,000 | 93,058,000 | 94,028,000 | 94,866,000 | 95,717,000 | 93,991,000 | 93,814,000 | 90,307,000 | 83,099,000 | 69,588,000 | 50,558,000 | 18,233,000 | 10,492,000 | 9,070,000 | 37,000 | 28,000 | 78,000 | 118,000 | 132,000 | 150,000 | 315,000 | 349,000 | 383,000 | 350,000 | 327,000 | 316,000 | 306,000 | 328,000 | ||||||||
intangible assets | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 9,505,000 | 9,743,000 | 9,982,000 | 10,220,000 | |||||||||||||||||||||||||||||||
operating lease right-to-use assets | 1,445,000 | 1,544,000 | 376,000 | 438,000 | 501,000 | 565,000 | 628,000 | 692,000 | 757,000 | 824,000 | 1,081,000 | 715,000 | 840,000 | 914,000 | |||||||||||||||||||||||||||||
other non-current assets | 4,285,000 | 2,175,000 | 1,299,000 | 931,000 | 910,000 | 951,000 | 951,000 | 961,000 | 960,000 | 1,129,000 | 1,051,000 | 292,000 | 385,000 | 384,000 | 360,000 | 379,000 | 379,000 | ||||||||||||||||||||||||||
total assets | 257,912,000 | 277,171,000 | 252,440,000 | 187,359,000 | 192,870,000 | 162,890,000 | 94,989,000 | 70,307,000 | 135,343,000 | 154,457,000 | 139,282,000 | 159,736,000 | 179,088,000 | 225,690,000 | 242,646,000 | 276,165,000 | 223,716,000 | 240,900,000 | 214,774,000 | 189,165,000 | 183,521,000 | 58,345,000 | 33,932,000 | 20,980,000 | 35,823,000 | 23,784,000 | 27,510,000 | 29,801,000 | 34,318,000 | 31,346,000 | 47,018,000 | 57,825,000 | 50,928,000 | 60,470,000 | 39,542,000 | 47,328,000 | 45,065,000 | 50,204,000 | 8,736,000 | 7,569,467 | 314,441 | 2,117,210 | 1,525,742 |
liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||||||
current liabilities: | |||||||||||||||||||||||||||||||||||||||||||
accounts payable | 9,649,000 | 8,114,000 | 8,540,000 | 7,783,000 | 4,193,000 | 4,546,000 | 3,935,000 | 10,406,000 | 6,649,000 | 3,782,000 | 7,799,000 | 7,673,000 | 8,016,000 | 8,068,000 | 4,556,000 | 9,568,000 | 9,397,000 | 13,282,000 | 7,964,000 | 3,406,000 | 2,859,000 | 3,189,000 | 1,408,000 | 1,264,000 | 1,179,000 | 841,000 | 872,000 | 944,000 | 1,935,000 | 2,067,000 | 3,049,000 | 2,422,000 | 2,770,000 | 1,986,000 | |||||||||
accrued expenses and other current liabilities | 19,836,000 | 22,598,000 | 12,332,000 | 11,083,000 | 7,718,000 | 10,667,000 | 8,151,000 | 8,540,000 | 10,733,000 | 12,482,000 | 9,500,000 | 10,333,000 | 4,619,000 | 9,680,000 | 8,280,000 | 5,830,000 | 5,560,000 | 7,945,000 | 3,479,000 | 4,211,000 | 2,783,000 | 1,143,000 | 996,000 | ||||||||||||||||||||
lease liability, short term | 162,000 | 125,000 | 159,000 | 195,000 | 235,000 | 274,000 | 275,000 | 277,000 | 277,000 | 270,000 | 434,000 | 432,000 | 504,000 | 489,000 | |||||||||||||||||||||||||||||
total current liabilities | 29,647,000 | 30,837,000 | 21,031,000 | 19,061,000 | 12,146,000 | 18,307,000 | 15,181,000 | 22,043,000 | 20,479,000 | 18,884,000 | 17,733,000 | 18,442,000 | 13,073,000 | 18,180,000 | 13,340,000 | 15,909,000 | 15,354,000 | 21,716,000 | 12,026,000 | 8,081,000 | 6,028,000 | 4,678,000 | 2,660,000 | 2,364,000 | 1,830,000 | 1,780,000 | 2,116,000 | 2,620,000 | 4,196,000 | 3,911,000 | 6,650,000 | 5,097,000 | 4,619,000 | 3,517,000 | 3,382,000 | 3,497,000 | 2,371,000 | 2,275,000 | 2,211,000 | 2,119,668 | 2,262,826 | 1,138,792 | 782,792 |
lease liability, long term | 1,128,000 | 1,184,000 | 266,000 | 297,000 | 328,000 | 358,000 | 425,000 | 493,000 | 563,000 | 632,000 | 716,000 | 328,000 | 382,000 | 467,000 | |||||||||||||||||||||||||||||
total liabilities | 30,775,000 | 32,021,000 | 21,297,000 | 19,358,000 | 12,474,000 | 23,332,000 | 20,778,000 | 28,204,000 | 27,200,000 | 48,932,000 | 18,449,000 | 19,273,000 | 13,661,000 | 18,508,000 | 13,722,000 | 16,383,000 | 15,759,000 | 22,183,000 | 12,556,000 | 8,672,000 | 6,605,000 | 4,773,000 | 2,685,000 | 2,369,000 | 1,854,000 | 1,809,000 | 2,149,000 | 2,696,000 | 4,284,000 | 4,008,000 | 6,756,000 | 5,174,000 | 4,684,000 | 3,584,000 | 3,450,000 | 3,551,000 | 2,401,000 | 2,281,000 | 2,224,000 | 2,133,418 | 2,277,963 | 1,158,502 | 810,849 |
commitments | |||||||||||||||||||||||||||||||||||||||||||
stockholders’ equity: | |||||||||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value... | |||||||||||||||||||||||||||||||||||||||||||
common stock, 0.001 par value... | 14,000 | 13,000 | 10,000 | 8,000 | 7,000 | 4,000 | 156,000 | 10,000 | 74,000 | 59,000 | 18,000 | 11,000 | 64,000 | 76,000 | 53,000 | 32,000 | 553,000 | 496,000 | 404,000 | 346,000 | 324,000 | 105,000 | 49,000 | 8,000 | 7,000 | 4,000 | 4,000 | 29,000 | 25,000 | 19,000 | 19,000 | 19,000 | 16,000 | 16,000 | 11,000 | 11,000 | 10,000 | 10,000 | 6,000 | 4,877 | 2,197 | 43,183 | 34,278 |
additional paid in capital | 1,122,315,000 | 1,100,141,000 | 1,039,212,000 | 944,058,000 | 928,178,000 | 870,503,000 | 782,891,000 | 736,709,000 | 723,906,000 | 706,356,000 | 694,371,000 | 686,025,000 | 682,566,000 | 677,311,000 | 667,389,000 | 637,770,000 | 593,759,000 | 578,133,000 | 532,162,000 | 491,957,000 | 464,841,000 | 292,058,000 | 255,601,000 | 187,914,000 | 185,055,000 | 168,283,000 | 166,604,000 | 160,823,000 | 156,171,000 | 143,667,000 | 142,658,000 | 141,653,000 | 122,010,000 | 120,890,000 | 90,423,000 | 89,120,000 | 80,586,000 | 79,804,000 | 33,235,000 | 28,452,448 | 17,965,425 | 16,759,805 | 12,163,973 |
accumulated deficit | -894,909,000 | -854,715,000 | -807,805,000 | -775,795,000 | -747,523,000 | -730,694,000 | -708,586,000 | -694,373,000 | -615,597,000 | -600,658,000 | -573,336,000 | -545,361,000 | -516,992,000 | -470,038,000 | -438,358,000 | -409,377,000 | -386,237,000 | -359,820,000 | -330,267,000 | -311,739,000 | -288,186,000 | -238,522,000 | -224,343,000 | -169,298,000 | -151,084,000 | -146,304,000 | -141,240,000 | -133,758,000 | -126,180,000 | -116,374,000 | -102,398,000 | -89,038,000 | -75,788,000 | -64,025,000 | -54,344,000 | -45,355,000 | -37,936,000 | ||||||
accumulated other comprehensive loss | -283,000 | -289,000 | -274,000 | -270,000 | -266,000 | -255,000 | -250,000 | -243,000 | -240,000 | -232,000 | -220,000 | -212,000 | -211,000 | -167,000 | -160,000 | -143,000 | -118,000 | -92,000 | -81,000 | -71,000 | -63,000 | -69,000 | -60,000 | -13,000 | -9,000 | -8,000 | 1,000 | ||||||||||||||||
total stockholders’ equity | 227,137,000 | 245,150,000 | 231,143,000 | 168,001,000 | 180,396,000 | 139,558,000 | 74,211,000 | 42,103,000 | 108,143,000 | 105,525,000 | 120,833,000 | 140,463,000 | 165,427,000 | 207,182,000 | 228,924,000 | 228,282,000 | 207,957,000 | 218,717,000 | 202,218,000 | 180,493,000 | 176,916,000 | 31,247,000 | |||||||||||||||||||||
total liabilities and stockholders’ equity | 257,912,000 | 277,171,000 | 252,440,000 | 187,359,000 | 192,870,000 | 162,890,000 | 94,989,000 | 70,307,000 | 135,343,000 | 154,457,000 | 139,282,000 | 179,088,000 | 225,690,000 | 242,646,000 | 223,716,000 | 240,900,000 | 214,774,000 | 189,165,000 | 183,521,000 | 33,932,000 | |||||||||||||||||||||||
term loan payable, short term | 2,820,000 | 2,820,000 | 2,820,000 | 2,820,000 | 2,350,000 | ||||||||||||||||||||||||||||||||||||||
term loan payable, long term | 4,667,000 | 5,172,000 | 5,668,000 | 6,158,000 | 6,561,000 | ||||||||||||||||||||||||||||||||||||||
goodwill | 965,000 | 965,000 | 965,000 | 965,000 | |||||||||||||||||||||||||||||||||||||||
series c warrant liabilities | 14,595,000 | ||||||||||||||||||||||||||||||||||||||||||
series d warrant liabilities | 8,260,000 | ||||||||||||||||||||||||||||||||||||||||||
series b convertible preferred stock, 0 shares designated as of both december 31, 2023 and 2022; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock, 0 shares designated as of both december 31, 2023 and december 31, 2022; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
receivables | 1,562,000 | ||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other | 9,544,000 | 12,012,000 | 11,751,000 | 10,548,000 | 11,161,000 | 14,769,000 | 12,554,000 | 10,389,000 | 12,112,000 | 11,550,000 | 8,951,000 | 2,605,000 | 2,731,000 | 1,429,000 | 1,130,000 | 1,009,000 | 1,019,000 | 2,483,000 | 2,414,000 | 3,168,000 | 3,343,000 | 2,142,000 | 1,577,000 | 1,805,000 | 852,000 | 699,000 | 946,000 | 554,000 | 429,000 | 46,401 | 46,362 | 224,659 | |||||||||||
series b convertible preferred stock, 0 shares designated as of both september 30, 2023 and december 31, 2022; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock, 0 shares designated as of both september 30, 2023 and december 31, 2022; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
right-of-use assets | 1,213,000 | 940,000 | 1,068,000 | 1,018,000 | 441,000 | ||||||||||||||||||||||||||||||||||||||
liabilities, redeembable convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||||||
lease liability, current | 436,000 | 438,000 | 511,000 | 397,000 | 583,000 | 464,000 | 386,000 | 346,000 | 256,000 | ||||||||||||||||||||||||||||||||||
lease liability, net of current portion | 831,000 | 474,000 | 530,000 | 591,000 | 95,000 | ||||||||||||||||||||||||||||||||||||||
series b convertible preferred stock, 0 shares designated as of both june 30, 2023 and december 31, 2022; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock, 0 shares designated as of both june 30, 2023 and december 31, 2022; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable convertible preferred stock and stockholders’ equity | 159,736,000 | 276,165,000 | |||||||||||||||||||||||||||||||||||||||||
right of use assets | 986,000 | 760,000 | 921,000 | 281,000 | |||||||||||||||||||||||||||||||||||||||
lease liability, net of current | 588,000 | 405,000 | 577,000 | 25,000 | |||||||||||||||||||||||||||||||||||||||
series b convertible preferred stock, 0 shares designated as of both march 31, 2023 and december 31, 2022; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock, 0 shares designated as of both march 31, 2023 and december 31, 2022; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
series b convertible preferred stock, 0 shares designated as of both december 31, 2022 and 2021; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock, 0 shares designated as of both december 31, 2022 and 2021; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
0 shares designated as of september 30, 2022 and december 31, 2021, 0 issued and outstanding as of september 30, 2022 and december 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||
restricted cash | 31,500,000 | 240,000 | 240,000 | 240,000 | 240,000 | 100,000 | 100,000 | 89,000 | 89,000 | 89,000 | 89,000 | 89,000 | 133,000 | 133,000 | 132,000 | 133,000 | 133,000 | 133,000 | 133,000 | 133,000 | 133,000 | 60,000 | 60,000 | 60,335 | 60,312 | 60,267 | 60,222 | ||||||||||||||||
redeemable convertible preferred stock, 0.001 par value... | |||||||||||||||||||||||||||||||||||||||||||
series a convertible redeemable preferred stock, 0.001 par value... | 26,250,000 | ||||||||||||||||||||||||||||||||||||||||||
series b convertible redeemable preferred stock, 0.001 par value... | 5,250,000 | ||||||||||||||||||||||||||||||||||||||||||
security deposit | 19,000 | 31,000 | 26,000 | 5,000 | 20,000 | 7,000 | 45,000 | ||||||||||||||||||||||||||||||||||||
intangible asset | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | |||||||||||||||||||||||||||
series b convertible preferred stock, 5,313 shares designated as of both december 31, 2021 and 2020; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock, 0 shares designated as of both december 31, 2021 and 2020; issued and outstanding - none | |||||||||||||||||||||||||||||||||||||||||||
series b convertible preferred stock, 0.001 par value... | |||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock, 0.001 par value... | |||||||||||||||||||||||||||||||||||||||||||
cash | 55,022,000 | 58,181,000 | 38,184,000 | 46,227,000 | 43,870,000 | 49,547,000 | 8,202,000 | 7,419,930 | 68,037 | 1,785,390 | 1,337,731 | ||||||||||||||||||||||||||||||||
liabilities and stockholders' equity | |||||||||||||||||||||||||||||||||||||||||||
stockholders' equity: | |||||||||||||||||||||||||||||||||||||||||||
total stockholders' equity | 53,572,000 | 18,611,000 | 33,969,000 | 21,975,000 | 25,361,000 | 27,105,000 | 30,034,000 | 27,338,000 | 40,262,000 | 52,651,000 | 46,244,000 | 56,886,000 | 36,092,000 | 43,777,000 | 42,664,000 | 47,923,000 | 6,512,000 | 5,436,049 | -1,963,522 | 958,708 | 714,893 | ||||||||||||||||||||||
total liabilities and stockholders' equity | 58,345,000 | 20,980,000 | 35,823,000 | 23,784,000 | 27,510,000 | 29,801,000 | 34,318,000 | 31,346,000 | 47,018,000 | 57,825,000 | 50,928,000 | 60,470,000 | 39,542,000 | 47,328,000 | 45,065,000 | 50,204,000 | 8,736,000 | 7,569,467 | 314,441 | 2,117,210 | 1,525,742 | ||||||||||||||||||||||
preferred stock, 5,000,000 shares authorized series b convertible preferred stock, 0.001 par value... | |||||||||||||||||||||||||||||||||||||||||||
security deposits | 11,000 | 11,000 | 11,000 | 11,000 | 56,000 | 56,000 | 56,000 | 57,000 | |||||||||||||||||||||||||||||||||||
accrued expenses | 1,100,000 | 651,000 | 939,000 | 1,244,000 | 1,676,000 | 2,261,000 | 1,844,000 | 3,601,000 | 2,675,000 | 1,849,000 | 1,531,000 | 853,859 | 601,588 | 309,800 | 292,744 | ||||||||||||||||||||||||||||
deferred rent payable | 5,000 | 24,000 | 29,000 | 33,000 | 76,000 | 88,000 | 97,000 | 106,000 | 68,000 | 54,000 | 30,000 | 6,000 | 13,000 | 13,750 | 15,137 | 19,710 | 28,056 | ||||||||||||||||||||||||||
marketable securities-available for sale, at fair value | 2,480,000 | 7,180,000 | 11,094,000 | 16,308,000 | 19,059,000 | ||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive income loss | -7,000 | ||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive income | 11,000 | 18,000 | 26,000 | -17,000 | 17,000 | 6,000 | 5,000 | 2,000 | 1,000 | 4,000 | |||||||||||||||||||||||||||||||||
marketable securities – available for sale, at fair value | 23,841,000 | 22,038,000 | |||||||||||||||||||||||||||||||||||||||||
deposits, long term | 56,000 | 45,000 | 45,000 | 45,000 | |||||||||||||||||||||||||||||||||||||||
deferred rent payable, long term | 77,000 | 65,000 | 67,000 | ||||||||||||||||||||||||||||||||||||||||
accounts payable, including 95 and 46 to related parties as of december 31, 2014 and 2013, respectively | 1,487,000 | ||||||||||||||||||||||||||||||||||||||||||
accrued expenses, including 595 and 491 to related parties as of december 31, 2014 and 2013, respectively | 1,895,000 | ||||||||||||||||||||||||||||||||||||||||||
promissory notes, related party | 280,000 | 280,000 | 280,000 | ||||||||||||||||||||||||||||||||||||||||
furniture and equipment | 224,000 | 71,000 | 43,000 | 45,000 | 42,801 | 38,814 | 46,894 | 53,248 | |||||||||||||||||||||||||||||||||||
security deposit, long term | 45,000 | ||||||||||||||||||||||||||||||||||||||||||
accounts payable, including 47 and 46 to related parties as of september 30, 2014 and december 31, 2013, respectively | 2,448,000 | ||||||||||||||||||||||||||||||||||||||||||
accrued expenses, including -0- and 491 to related parties as of september 30, 2014 and december 31, 2013, respectively | 1,049,000 | ||||||||||||||||||||||||||||||||||||||||||
accounts payable, including 92 and 46 to related parties as of june 30, 2014 and december 31, 2013, respectively | 1,518,000 | ||||||||||||||||||||||||||||||||||||||||||
accrued expenses, including 3 and 491 to related parties as of june 30, 2014 and december 31, 2013, respectively | 573,000 | ||||||||||||||||||||||||||||||||||||||||||
accounts payable, including 72 and 46 to related parties as of march 31, 2014 and december 31, 2013, respectively | 1,399,000 | ||||||||||||||||||||||||||||||||||||||||||
accrued expenses, including -0- and 491 to related parties as of march 31, 2014 and december 31, 2013, respectively | 596,000 | ||||||||||||||||||||||||||||||||||||||||||
deficit accumulated during development stage | -31,892,000 | -26,728,000 | -23,021,276 | -19,931,144 | -15,844,280 | -11,483,358 | |||||||||||||||||||||||||||||||||||||
accounts payable, including 46 and 7 to related parties as of december 31, 2013 and 2012, respectively | 765,000 | ||||||||||||||||||||||||||||||||||||||||||
accrued expenses, including 491 and 21 to related parties as of december 31, 2013 and 2012, respectively | 1,166,000 | ||||||||||||||||||||||||||||||||||||||||||
accrued interest, related party | |||||||||||||||||||||||||||||||||||||||||||
other assets: | |||||||||||||||||||||||||||||||||||||||||||
accounts payable, including 80,210 and 6,809 to related parties as of september 30, 2013 and december 31, 2012, respectively | 985,809 | ||||||||||||||||||||||||||||||||||||||||||
promissory notes, related parties | 280,000 | ||||||||||||||||||||||||||||||||||||||||||
deferred offering costs | 100,916 | ||||||||||||||||||||||||||||||||||||||||||
accounts payable, including 62,565 and 6,809 to related parties as of june 30, 2013 and december 31, 2012, respectively | 1,461,238 | ||||||||||||||||||||||||||||||||||||||||||
advances, related party | 200,000 | ||||||||||||||||||||||||||||||||||||||||||
stockholders' equity | |||||||||||||||||||||||||||||||||||||||||||
deferred financing costs | |||||||||||||||||||||||||||||||||||||||||||
accounts payable, including 6,809 and 27,483 to related parties as of december 31, 2012 and 2011, respectively | 825,837 | ||||||||||||||||||||||||||||||||||||||||||
accrued interest, including 3,155 and 5,006 to related parties as of december 31, 2012 and 2011, respectively | 3,155 | ||||||||||||||||||||||||||||||||||||||||||
liability to placement agent | |||||||||||||||||||||||||||||||||||||||||||
convertible debentures | |||||||||||||||||||||||||||||||||||||||||||
convertible debentures, including 265,000 to related parties | |||||||||||||||||||||||||||||||||||||||||||
prepaid expenses | 74,541 | ||||||||||||||||||||||||||||||||||||||||||
accounts payable, including 53,891 and 27,483 to related parties as of june 30, 2012 and december 31, 2011, respectively | 486,938 | ||||||||||||||||||||||||||||||||||||||||||
accrued interest, including 3,111 and 5,006 to related parties as of june 30, 2012 and december 31, 2011, respectively | 3,111 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss | -40,194,000 | -46,910,000 | -32,010,000 | -28,272,000 | -16,829,000 | -22,108,000 | -14,213,000 | -78,776,000 | -14,939,000 | -27,322,000 | -27,975,000 | -28,356,000 | -33,005,000 | -31,680,000 | -28,981,000 | -23,140,000 | -26,417,000 | -29,553,000 | -18,528,000 | -23,553,000 | -20,653,000 | -17,021,000 | -11,990,000 | -14,179,000 | -7,273,000 | -8,707,000 | -7,838,000 | -5,840,000 | -6,233,000 | -7,588,000 | -5,479,000 | -6,087,000 | -6,935,000 | -5,493,000 | -5,786,000 | -4,780,000 | -5,064,000 | -7,482,000 | -7,578,000 | -9,806,000 | -13,976,000 | -13,360,000 | -13,250,000 | -11,763,000 | -9,681,000 | -8,989,000 | -7,419,000 | -6,044,000 | -5,164,000 | -3,707,004 | -3,090,132 | -2,085,661 | -2,001,203 | -2,628,895 | -1,732,027 | -3,073,690 | -2,014,988 |
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 555,000 | 488,000 | 461,000 | 483,000 | 493,000 | 496,000 | 510,000 | 1,205,000 | 1,210,000 | 1,261,000 | 1,216,000 | 921,000 | 893,000 | 836,000 | 252,000 | 102,000 | 63,000 | 27,000 | 10,000 | 7,000 | 6,000 | 7,000 | 8,000 | 6,000 | 6,000 | 5,000 | 5,000 | 7,000 | 9,000 | 15,000 | 24,000 | 43,000 | 50,000 | 56,000 | 57,000 | 71,000 | |||||||||||||||||||||
amortization of debt discount | 0 | 0 | 65,000 | 209,000 | 129,000 | 302,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
loss on extinguishment of debt | 0 | 0 | 0 | 2,092,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation | 1,970,000 | 1,789,000 | 1,923,000 | 1,423,000 | 882,000 | 894,000 | 1,038,000 | 1,154,000 | 1,692,000 | 2,038,000 | 2,079,000 | 2,364,000 | 2,794,000 | 2,716,000 | 2,765,000 | 2,813,000 | 2,620,000 | 2,296,000 | 2,302,000 | 2,089,000 | 1,212,000 | 871,000 | 912,000 | 733,000 | 360,000 | 359,000 | 362,000 | 431,000 | 305,000 | 368,000 | 451,000 | 409,000 | 399,000 | 313,000 | 433,000 | 477,000 | 567,000 | 899,000 | 744,000 | 727,000 | 896,000 | 1,005,000 | |||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | -2,548,000 | -2,789,000 | -1,193,000 | 992,000 | 371,000 | 1,299,000 | -1,643,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other | -278,000 | -1,002,000 | -617,000 | 2,943,000 | -341,000 | 2,366,000 | -1,355,000 | -1,761,000 | 3,066,000 | 1,474,000 | -1,206,000 | 3,628,000 | -2,215,000 | -2,166,000 | -566,000 | -2,622,000 | 1,971,000 | -3,736,000 | 113,000 | -39,000 | -1,700,000 | -481,000 | -1,234,000 | ||||||||||||||||||||||||||||||||||
other non-current assets | -3,742,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
inventory | 2,369,000 | 364,000 | 1,220,000 | -130,000 | 272,000 | 50,000 | 1,247,000 | 1,156,000 | 1,288,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 1,533,000 | -738,000 | 1,021,000 | 3,064,000 | -353,000 | 581,000 | -6,357,000 | 3,727,000 | 2,976,000 | -3,936,000 | 1,017,000 | -1,146,000 | 575,000 | 3,034,000 | -2,515,000 | 1,549,000 | -3,113,000 | 156,000 | 4,561,000 | 548,000 | -1,739,000 | 2,829,000 | -1,419,000 | 1,780,000 | -1,662,000 | 1,948,000 | 73,000 | -88,000 | -270,000 | 355,000 | -591,000 | 374,000 | -32,000 | -66,000 | 183,000 | 338,000 | -31,000 | -71,000 | -997,000 | -131,000 | -986,000 | 635,000 | -337,000 | 783,000 | 502,000 | -960,000 | 934,000 | 119,000 | 635,000 | -219,972 | -475,429 | 591,142 | 44,259 | 128,454 | 210,445 | 304,530 | -512,790 |
operating lease liabilities and rou asset | 80,000 | -5,000 | 2,000 | 11,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued expenses and other current liabilities | -2,063,000 | 10,082,000 | 1,250,000 | 3,363,000 | -2,950,000 | 1,548,000 | 475,000 | 913,000 | -1,746,000 | 4,426,000 | -1,047,000 | 1,364,000 | -2,957,000 | 2,207,000 | 1,313,000 | -283,000 | -2,032,000 | 2,895,000 | -732,000 | 1,428,000 | -1,843,000 | 2,554,000 | 930,000 | 146,000 | -716,000 | 848,000 | |||||||||||||||||||||||||||||||
net cash from operating activities | -42,318,000 | -39,650,000 | -28,782,000 | -14,833,000 | -16,579,000 | -14,630,000 | -18,801,000 | -9,919,000 | -17,575,000 | -22,340,000 | -23,385,000 | -23,367,000 | -32,911,000 | -22,301,000 | -23,535,000 | -21,171,000 | -31,046,000 | -22,445,000 | -12,946,000 | -19,108,000 | -21,058,000 | -13,914,000 | -15,285,000 | -10,041,000 | -9,326,000 | -6,714,000 | -6,614,000 | -4,716,000 | -8,639,000 | -6,824,000 | -4,891,000 | -5,485,000 | -6,771,000 | -4,927,000 | -5,047,000 | -4,360,000 | -4,794,000 | -5,443,000 | -8,392,000 | -7,995,000 | -15,485,000 | -11,912,000 | -12,325,000 | -9,238,000 | -9,053,000 | -8,218,000 | -4,859,000 | -5,699,000 | -4,064,000 | -3,531,049 | -2,862,893 | -761,429 | -1,361,629 | -1,505,240 | -1,300,197 | -1,129,813 | -1,777,614 |
capital expenditures | -1,526,000 | -1,272,000 | -1,225,000 | -527,000 | -6,000 | -3,000 | -9,000 | 0 | -607,000 | -2,702,000 | -1,044,000 | -3,436,000 | 1,731,000 | -10,180,000 | -15,265,000 | -21,341,000 | -25,622,000 | -7,751,000 | -1,429,000 | -505,000 | -4,534,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
free cash flows | -43,844,000 | -40,922,000 | -30,007,000 | -15,360,000 | -16,585,000 | -14,633,000 | -18,810,000 | -9,919,000 | -22,947,000 | -26,087,000 | -24,411,000 | -36,347,000 | -20,570,000 | -33,715,000 | -36,436,000 | -52,387,000 | -48,067,000 | -20,697,000 | -20,537,000 | -21,563,000 | -18,448,000 | -15,285,000 | -10,041,000 | -9,326,000 | -6,714,000 | -6,614,000 | -4,716,000 | -8,639,000 | -6,824,000 | -4,894,000 | -5,485,000 | -6,771,000 | -4,927,000 | -5,047,000 | -4,360,000 | -4,794,000 | -5,443,000 | -8,392,000 | -7,995,000 | -15,485,000 | -11,912,000 | -12,325,000 | -9,238,000 | -9,053,000 | -8,218,000 | -4,859,000 | -5,699,000 | -4,064,000 | -3,531,049 | -2,862,893 | -761,429 | -1,361,629 | -1,505,240 | -1,300,197 | -1,129,813 | -1,777,614 | |
cash flows from investing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of property and equipment | -1,692,000 | -1,874,000 | -962,000 | -527,000 | -6,000 | -3,000 | -9,000 | 0 | -108,000 | -438,000 | -1,813,000 | -1,845,000 | -3,799,000 | -4,671,000 | -8,820,000 | -14,439,000 | -20,217,000 | -25,622,000 | -7,751,000 | -1,429,000 | -505,000 | -4,534,000 | -3,000 | 0 | |||||||||||||||||||||||||||||||||
net cash from investing activities | -1,692,000 | -1,021,000 | -962,000 | -2,539,000 | -6,000 | -3,000 | -9,000 | 0 | -108,000 | -431,000 | -821,000 | -24,019,000 | -3,799,000 | -4,671,000 | -8,820,000 | -14,439,000 | -20,217,000 | -25,622,000 | -7,751,000 | -1,429,000 | -505,000 | -4,534,000 | -3,000 | 0 | 2,478,000 | 4,694,000 | 3,901,000 | 5,241,000 | 2,734,000 | 4,718,000 | -1,925,000 | -22,093,000 | -125,000 | -160,000 | -105,000 | -2,000 | -6,792 | -8,163 | -23 | -22 | -23 | -1,881 | -33,837 | -22 | |||||||||||||
cash flows from financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of term loan | 0 | 0 | -9,650,000 | -705,000 | -705,000 | -235,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
repurchase of common stock | 0 | -2,902,000 | -3,047,000 | 0 | 0 | 0 | -13,965,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from espp | 79,000 | 0 | 4,000 | 0 | 23,000 | 0 | 0 | 0 | 29,000 | 0 | 0 | 0 | 40,000 | 0 | 68,000 | 0 | 28,000 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||
proceeds, net issuance costs paid of 676 and 2,270, from sale of common stock | 20,126,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from financing activities | 20,205,000 | 59,143,000 | 94,861,000 | 10,993,000 | 49,533,000 | 85,154,000 | 42,905,000 | 7,025,000 | -212,000 | 40,714,000 | 6,274,000 | 1,029,000 | -11,500,000 | 7,229,000 | -4,625,000 | 72,177,000 | 13,063,000 | 43,767,000 | 37,961,000 | 22,049,000 | 108,710,000 | 39,859,000 | 20,069,000 | 34,420,000 | 28,757,000 | 7,945,000 | 4,484,000 | 420,000 | 70,000 | 17,187,000 | 2,890,000 | 2,930,000 | 532,000 | 1,118,000 | 1,000 | 16,298,000 | 1,102,000 | 4,857,000 | 3,858,000 | 0 | 18,694,000 | -54,000 | 29,054,000 | 303,000 | 7,371,000 | 131,000 | 45,412,000 | 4,321,301 | 10,222,949 | 3,255,000 | 0 | -1 | 4,237,895 | ||||
effect of currency rate change on cash | 6,000 | -14,000 | -4,000 | -4,000 | -9,000 | 24,000 | -17,000 | 1,000 | -4,000 | -10,000 | -12,000 | 0 | -43,000 | -5,000 | -20,000 | -24,000 | -25,000 | -10,000 | -13,000 | -7,000 | -1,000 | 0 | 7,000 | -8,000 | -15,000 | -1,000 | 6,000 | 1,000 | -10,000 | -3,000 | 9,000 | -17,000 | -2,000 | -2,000 | 1,000 | -18,000 | -1,000 | -11,000 | 19,000 | 3,000 | -4,000 | 1,000 | -4,000 | -4,000 | -1,000 | ||||||||||||
net increase in cash, cash equivalents and restricted cash | -23,799,000 | 18,458,000 | 65,113,000 | -6,383,000 | 32,939,000 | 70,545,000 | -19,748,000 | -37,000,000 | 36,543,000 | -38,225,000 | -4,310,000 | 17,251,000 | 1,505,000 | 87,146,000 | 21,411,000 | 775,000 | 10,361,000 | -1,995,000 | -2,574,000 | -6,243,000 | |||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash beginning of the period | 209,807,000 | 0 | 0 | 0 | 99,680,000 | -1,000 | 0 | 0 | 25,850,000 | 0 | 0 | 0 | 120,470,000 | 0 | 0 | 0 | 178,900,000 | 0 | 0 | 0 | 77,308,000 | 0 | 0 | 0 | 11,349,000 | 0 | 0 | 25,134,000 | 0 | 0 | 25,585,000 | ||||||||||||||||||||||||||
cash, cash equivalents and restricted cash end of period | 186,008,000 | 18,458,000 | 65,113,000 | -6,383,000 | 132,619,000 | 70,544,000 | 24,078,000 | -2,893,000 | 7,951,000 | 17,933,000 | -17,944,000 | -46,357,000 | 72,217,000 | -19,748,000 | -37,000,000 | 36,543,000 | 140,675,000 | -4,310,000 | 17,251,000 | 1,505,000 | 164,454,000 | 21,411,000 | 775,000 | 24,357,000 | 30,765,000 | -2,126,000 | -4,298,000 | 16,548,000 | 19,342,000 | ||||||||||||||||||||||||||||
supplemental disclosures of cash flow information: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest paid | 0 | 117,000 | -115 | 0 | -40 | 3,155 | 0 | 0 | 0 | 35,195 | |||||||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment including in accounts payable and accrued liabilities | 166,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bad debt expense | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
asset impairment charges | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of warrant liabilities | 0 | 0 | 855,000 | -7,005,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on note | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
inventory write-off | -649,000 | -962,000 | -528,000 | 280,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of debt discounts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance costs of derivative instrument | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of note | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from note | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred payment related to purchase of business | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of term loan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 8,750 and 7,238 expenses, from sale of common stock and warrants, respectively | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repurchase of common stock, net of 30 expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non cash investing and financing activity: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment included in accounts payable and accrued liabilities | 602,000 | -263,000 | -169,000 | -889,000 | 801,000 | 363,000 | 6,402,000 | -1,360,000 | -826,000 | -1,124,000 | |||||||||||||||||||||||||||||||||||||||||||||||
net atm proceeds received after year-end | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance costs from derivative instruments | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
new operating leases and lease amendments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bad debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance costs of derivative instruments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
lease liabilities and rou asset | -6,000 | -6,000 | 12,000 | -5,000 | 3,000 | -1,000 | -5,000 | -12,000 | 43,000 | 10,000 | 0 | -2,000 | |||||||||||||||||||||||||||||||||||||||||||||
deferred payment related to purchase a business | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 5,750 and 3,942 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense paid | 301,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash financing and investing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
at-the-market agreement receivable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of a business | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 2,757 and 1,704 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net atm proceeds received after quarter-end | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 2,270 and 0, from sale of common stock | 62,230,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
offering costs allocated to warrant liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of business | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
disposal of property and equipment | 7,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redemption of convertible preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from debt financing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 7,238 and 2,800 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from allocated warrant liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
debt financing costs included in accrued liabilities and other current liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance costs included in accrued liabilities and other current liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 3,942 and 863 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 1,704 and 137 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | -2,893,000 | -17,899,000 | 17,933,000 | -17,944,000 | -46,357,000 | -48,253,000 | 19,416,000 | 1,225,000 | -2,126,000 | -4,298,000 | -8,586,000 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 0 and 101, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 6,659 expenses, from sale of convertible redeemable preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 2,800 and 3,078 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock deemed dividend | 2,404,000 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 0 and 4,255 expenses, from sale of convertible redeemable preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redemption of convertible redeemable preferred stock | -15,750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 863 and 2,738 expenses, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 4,255, from sale of convertible redeemable preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 137 and 1,933 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 101 and 8,328, from sale of common stock and warrants | 2,436,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock issued to acquire in-process research and development | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses | 70,000 | 295,000 | -51,000 | 234,000 | -121,000 | 10,000 | 1,503,000 | -63,000 | 752,000 | 178,000 | 228,000 | -953,000 | -155,000 | 239,000 | -381,000 | -126,000 | -382,258 | -39 | 21,329 | 156,968 | -181,583 | 31,465 | -10,494 | 38,383 | |||||||||||||||||||||||||||||||||
proceeds from exercise of warrants | 0 | 0 | 0 | 2,422,000 | 0 | 0 | 0 | 0 | 0 | 303,000 | 469,000 | 131,000 | 4,758,000 | 4,321,334 | 0 | ||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 3,078 and 10,505 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 4,255 expenses, from sale of convertible redeemable preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 2,738 and 9,329 expenses, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 1,933 and 8,940 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the exercise of warrants | 2,000 | 7,474,000 | 70,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 507 and 8,328, from sale of common stock and warrants | 13,023,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 0 and 711 expenses, from sale of preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 10,505 and 4,646 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
warrants deemed dividend | 0 | 0 | 0 | 451,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock and deemed dividend | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 9,329 and 3,740 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
series b convertible preferred stock and deemed dividend | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 8,940 and 2,644 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
series b convertible preferred stock deemed dividend | 0 | 1,260,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 0 and 711, from the sale of preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 8,328 and 1,513, from sale of common stock and warrants | 108,680,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 711 and 957 expenses, from sale of preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 4,646 and 1,045 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
beneficial conversion feature in connection with sale of series a convertible preferred stock and deemed dividend | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 711 and 0 expenses, from sale of preferred stock | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 3,740 and 485 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of furniture and fixtures | -5,000 | -2,000 | -3,000 | -7,000 | -2,000 | 0 | 0 | -1,000 | -65,000 | -50,000 | -35,000 | -159,000 | -33,000 | -2,000 | -6,860 | 0 | -1,859 | ||||||||||||||||||||||||||||||||||||||||
net cash used by investing activities | -2,000 | -3,000 | -7,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 2,644 and 1 expenses, from sale of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 711 and 0, from the sale of preferred stock | 4,602,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,513 and 0, from sale of common stock and warrants | 16,681,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 957 and 1,159 expenses, from sale of preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 1,045 and 610 expenses, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash beginning of the year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
taxes paid | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non cash financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating lease liabilities | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 485 and 172 expenses, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock under employee benefit plan | 28,000 | 0 | 3,000 | 64,000 | 0 | 10,000 | 54,000 | 0 | 113,000 | 0 | 90,000 | ||||||||||||||||||||||||||||||||||||||||||||||
accrued expenses and other liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 1 and 95 expenses, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued expenses and deferred rent | -750,000 | -40,000 | 420,000 | -233,000 | 263,000 | 349,000 | -120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 45, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
maturities of marketable securities | 0 | 0 | 2,480,000 | 4,694,000 | 3,900,000 | 5,197,000 | 2,735,000 | 4,783,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 1,159 expenses, from sale of preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of 610 and 1,183 expenses, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of premium on marketable securities | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation of property and equipment | 13,000 | 16,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
security deposit | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash (used) provided by investing activities | -2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 172 and 1,168, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, end of period | -1,995,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 95 and 1,168, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 45 and 34, respectively from sale of common stock | 532,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,183 and 1,866, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, beginning of the year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock under employee stock purchase plan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from restricted cash | 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,168 and 1,294, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | -5,045,000 | -15,728,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, beginning of the period | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, end of period | -5,045,000 | 706,000 | -15,728,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,168 and 1,065, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued expenses | -307,000 | -465,000 | -508,000 | 428,000 | -1,645,000 | 926,000 | 919,000 | 318,000 | -289,000 | 856,000 | 450,000 | -5,000 | -572,000 | 313,741 | 252,270 | 253,996 | 35,993 | 167,051 | -156,441 | 194,012 | 88,503 | ||||||||||||||||||||||||||||||||||||
deferred rent payable | 7,000 | -40,000 | -21,000 | -9,000 | 45,000 | 12,000 | 9,000 | 47,000 | 1,000 | -2,000 | -1,386 | -1,387 | -1,387 | -1,387 | -513 | -514 | -513 | ||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 34 from sale of common stock | 1,102,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash | 1,002,000 | -10,748,000 | 19,997,000 | -8,043,000 | -1,361,651 | 1,749,737 | -1,302,078 | -1,163,651 | 2,460,259 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash, beginning of the period | 18,941,000 | 19,175,000 | 38,184,000 | 0 | 0 | 0 | 8,202,000 | -390 | 0 | 0 | 1,785,390 | 0 | 0 | 0 | 41,123 | ||||||||||||||||||||||||||||||||||||||||||
cash, end of period | 19,943,000 | 8,427,000 | 58,181,000 | -8,043,000 | 2,357,000 | -5,677,000 | 49,547,000 | 782,070 | 7,351,893 | -355,702 | 423,739 | 1,749,737 | -1,302,078 | -1,163,651 | 2,501,382 | ||||||||||||||||||||||||||||||||||||||||||
other long term liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of intangible asset | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of marketable securities | -6,585,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,866 and 3,484, from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | 3,297,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, beginning of the year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,294 and 2,115 from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,065 and 2,115 from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 2,061 from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
warrants issued for services rendered | 20,828 | 6,099 | 13,638 | 10,435 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock issued in exchange for intellectual property | 0 | 0 | 0 | 608,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued interest | 0 | 0 | -3,155 | 3,155 | 0 | 0 | -35,195 | ||||||||||||||||||||||||||||||||||||||||||||||||||
increase in restricted cash balance | -1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from related party promissory notes | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 3,484, 3,460 and 3,454 from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of related party promissory notes | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 3,484 and 3,460 from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation | 23,000 | 22,000 | 6,000 | 5,000 | 4,000 | 4,767 | 4,153 | 3,942 | 4,138 | 4,137 | 4,076 | 3,762 | 2,354 | ||||||||||||||||||||||||||||||||||||||||||||
stock based compensation | 1,174,000 | 1,348,000 | 651,000 | 553,000 | 441,534 | 441,571 | 441,572 | 392,323 | 293,828 | 342,798 | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 2,115 and 2,824 from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred rent payable, long term | -2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 2,061 and 2,824 from sale of common stock | 29,054,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
noncash financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuances of common stock under employee benefit plan | 70,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash deposit in connection with lease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 3,460 and 3,454 from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net proceeds from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from related party advances | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred offering costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 2,824 from sale of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase increase in cash | -5,677,000 | 41,345,000 | 7,351,893 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
non cash investing and financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred financing costs capitalized | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization and write off of deferred financing costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non cash interest, consisting of beneficial conversion feature in connection with convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non cash interest, consisting of common stock and warrants issued in connection with convertible debentures | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash financing costs related to january and march 2012 financing | 0 | 0 | 0 | 81,337 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of warrant liability | -47,023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of restricted cash and interest earned on restricted cash | -23 | -23 | -22 | -23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from demand notes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from other notes payable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 24 as of december 31, 2011 from convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayment of convertible debentures | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,352 (2013) and 506 (2012), from sale of units consisting of common stock and warrants, respectively | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 2,824 (2014) from sale of common stock | 40,654,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
senior convertible notes exchanged for preferred shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
capital contribution of accrued interest | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
demand notes together with accrued interest converted into capital stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock issued for deferred financing costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
exchange of notes payable for convertible debenture | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
warrants liability reclassified to stockholders' equity | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
exchange of convertible debenture for units consisting of common stock and warrants | 710,000 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,352 (2013) and 506 (2012), from sale of units consisting of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of capital stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non cash interest, consisting of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued in connection with convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 24,000, from convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 1,351,987, 374,870, and 1,726,857, from sale of units consisting of common stock and warrants, respectively | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest, consisting of beneficial conversion feature in connection with convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest, consisting of common stock and warrants issued in connection with convertible debentures | 426,152 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from security deposit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 24,000 from convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 374,870, from sale of units consisting of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 24,000 as of december 31, 2011, from convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 374,870 from sale of units consisting of common stock and warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization and write down of deferred financing costs | 0 | 0 | 196,166 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss in change in fair value of warrant liability | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 304,870, from sale of units consisting of common stock and warrants | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest earned on restricted cash | -23 | -22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses of 74,000 from convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in cash overdraft | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from notes payable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(repayments) proceeds from convertible debentures | -150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds, net of expenses 304,870, from january and march 2012 financing | 4,387,895 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
warrants issued in connection with january and march 2012 financing charged to stockholders’ deficiency | 130,898 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of deferred financing costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of furniture and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayment of security deposit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of restricted cash | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from convertible debentures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
capital contribution of accrued interest on convertible notes |